Table 2.
Prospective analysis of EPA-DHA intake (100 mg/day) on all-cause and CV mortality in RTR.
| Model | EPA-DHA Intake, 100 mg/Day | |
|---|---|---|
| HR (95% CI) | p | |
| All-cause mortality | ||
| Model 1 | 0.87 (0.77–0.99) | 0.03 |
| Model 2 | 0.85 (0.75–0.97) | 0.02 |
| Model 3 | 0.87 (0.77–1.00) | 0.04 |
| Model 4 | 0.87 (0.76–0.99) | 0.03 |
| Model 5 | 0.84 (0.73–0.96) | 0.01 |
| Model 6 | 0.85 (0.74–0.97) | 0.02 |
| CV mortality | ||
| Model 1 | 0.85 (0.69–1.05) | 0.13 |
| Model 2 | 0.83 (0.68–1.02) | 0.08 |
| Model 3 | 0.86 (0.70–1.07) | 0.18 |
| Model 4 | 0.84 (0.68–1.03) | 0.10 |
| Model 5 | 0.81 (0.64–1.01) | 0.06 |
| Model 6 | 0.82 (0.65–1.03) | 0.08 |
RTR, renal transplant recipients; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; CV, cardiovascular. Model 1: adjustment for age and sex. Model 2: model 1 + adjustment for estimated glomerular filtration Rate, proteinuria, and time between transplantation and baseline measurement. Model 3: model 2 + adjustment for smoking status, alcohol use, and physical activity. Model 4: model 2 + adjustment for body mass index, diabetes mellitus and cardiovascular history. Model 5: model 2 + adjustment for total cholesterol, low-density lipoprotein-cholesterol, triglycerides concentration, and systolic blood pressure. Model 6: model 2 + adjustment for high-sensitivity C-reactive protein and albumin concentration.